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Neilan et al. (1) have investigated the prognostic role of left
ventricular myocardial scar in patients with atrial ﬁbrillation and
noted that the presence of late gadolinium enhancement (LGE)
predicts mortality compared with the absence of LGE. It would
be interesting to know whether the mortality differs according to
the type (transmural, subendocardial, and nonmyocardial) and
the extent of LGE, because the presence of transmural
enhancement has been shown to be associated with heart failure
compared with nontransmural enhancement (2). Neilan et al. (1)
also noted that, in patients with atrial ﬁbrillation referred for
cardiac magnetic resonance, the presence of LGE predicts
mortality compared with the absence of LGE. Atrial ﬁbrillation
(3) and the presence of LGE (4) have been shown to predict
mortality. It would be interesting to know whether the presence
of LGE has any incremental prognostic value in patients with
atrial ﬁbrillation.*Arun Kannan, MD
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We thank Drs. Kannan and Balamuthusamy for their interest in
our report (1) and appreciate the opportunity to reply. Among our
entire cohort of 720 patients, 44 of the 108 cases of abnormal late
gadolinium enhancement (LGE) were non–infarct-appearing LGE
(epicardial, midmyocardial, or patchy) and 64 cases were infarct
appearing (Table 2 in our report). Thus, in our observation cohort,
infarct-appearing LGE was the dominant factor that accounted for
the prognostic association between LGE and mortality in patients
with atrial ﬁbrillation referred for cardiac magnetic resonance. In
our subanalysis with patients with infarct LGE excluded, as shown
in Table 5 in our report, non–infarct-appearing LGE also showed
a strong association with mortality (hazard ratio: 4.21; p < 0.0001).
Therefore, based on our experience, patients with atrial ﬁbrillation
referred for cardiac magnetic resonance may have LGE as a result
of either infarction or noncoronary pathology, and both of these
ﬁndings portend an elevated risk of mortality. Regarding the
different patterns of noninfarct LGE (epicardial, midmyocardial,
or patchy), our study was not designed or powered to assess their
respective prognostic associations with patient mortality.*Tomas G. Neilan, MD
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